CA
NZ
UK
AU
IND
US
Outlook Therapeutics (NASDAQ: OTLK) received a materially upgraded price target from Ascendiant Capital, which raised its valuation target by more than two-thirds to $10 while simultaneously reiterating its Buy recommendation. The revision places Outlook Therapeutics among the more prominently upgraded small-cap ophthalmology stocks in …
Adial Pharmaceuticals (NASDAQ: ADIL) announced the acquisition of Azora Therapeutics Inc., gaining lead drug candidate AT177, which is being developed for the treatment of ulcerative colitis, a chronic inflammatory bowel disease affecting millions of patients globally.
A significant cluster of clinical-stage biotechs listed on Nasdaq disclosed material developments across the same week in June 2026, spanning Phase 3 trial initiations, analyst price target revisions, international commercialisation agreements, and pipeline-expanding acquisitions. The breadth of activity across multiple therapeutic areas and strategic …
MBX Biosciences (NASDAQ: MBX) reported one-year follow-up data from the open-label extension of its Phase 2 trial of canvuparatide, a once-weekly parathyroid hormone replacement candidate in development for hypoparathyroidism, a rare endocrine disorder characterised by insufficient PTH production.
Caribou Biosciences (NASDAQ: CRBU) delivered a landmark data moment for the broader allogeneic CAR-T therapy field at the European Hematology Association 2026 Annual Meeting, presenting Phase 1 results in both large B-cell lymphoma and multiple myeloma that challenge the long-held clinical dominance of autologous …
A three-judge panel of the 9th US Circuit Court of Appeals heard oral arguments in a case that may set a foundational legal precedent for how agentic AI systems are regulated under existing US law. The dispute between Amazon (NASDAQ: AMZN) and AI startup …
Eikon Therapeutics (NASDAQ: EIKN) appointed Ma. Fatima D. Francisco as an independent Class I director to the company's board of directors, effective June 15, 2026. Francisco brings consumer industry experience to a board that has been predominantly composed of scientific and financial backgrounds typical …
MBX Biosciences (NASDAQ: MBX) is preparing to initiate a Phase 3 clinical trial for canvuparatide in hypoparathyroidism in the third quarter of 2026, marking the most significant operational milestone in the company's development timeline for its lead rare disease asset.
CEL-SCI Corporation (NYSE: CVM) disclosed plans to finalise a commercialisation and distribution partnership with Saudi Amarox for Multikine, its cancer immunotherapy candidate, at the BIO 2026 global biotech conference. The agreement is structured around a 50/50 revenue-sharing model targeting the Saudi Arabian oncology market.
Agentic AI has established itself as the defining investment theme of 2026, moving well beyond the technology sector to reshape capital allocation, regulatory frameworks, and competitive dynamics across the global economy. Unlike the large language model wave of 2023 and 2024, which was concentrated …
Please wait processing your request...